Key Documents

View All Documentation

B4312

BTK, active, His tagged human

Name: BTK, active, His tagged human
Brand: SIGMA

PRECISIO^® Kinase, recombinant, expressed in baculovirus infected Sf9 cells, ≥70% (SDS-PAGE), buffered aqueous glycerol solution

Synonym(s):

AGMX1, AT, ATK, BPK, IMD1, PSCTK, XLA

Select a Size

Change View

About This Item

NACRES:

NA.32

UNSPSC Code:

12352200

Specific activity:

37-49 nmol/min·mg

Assay:

≥70% (SDS-PAGE)

Biological source:

human

Recombinant:

expressed in baculovirus infected Sf9 cells

Technical Service

Need help? Our team of experienced scientists is here for you.

Let Us Assist

biological source

human

Quality Level

100

recombinant

expressed in baculovirus infected Sf9 cells

product line

PRECISIO^® Kinase

assay

≥70% (SDS-PAGE)

form

buffered aqueous glycerol solution

specific activity

37-49 nmol/min·mg

mol wt

~78 kDa

solubility

water: soluble

UniProt accession no.

Q06187

application(s)

life science and biopharma

shipped in

dry ice

storage temp.

−70°C

Gene Information

human ... BTK(695)

Biochem/physiol Actions

BTK (also known as Bruton tyrosine kinase) plays a crucial role in B-lymphocyte differentiation and activation. BTK interacts with SRC homology 3 domains of FYN, LYN and HCK that are activated upon stimulation of B- and T-cell receptors.Defects in the BTK gene cause Agammaglobulinemia, an X-linked immunodeficiency characterized by failure to produce mature B lymphocyte cells and associated with a failure of Ig heavy chain rearrangement. The unique role of BTK makes it a desirable target for potential anti-cancer, anti-inflammatory and anti-viral agents as well as other treatments.

Physical form

Supplied in 50mM NaPhosphate pH 7.0, 300 mM NaCl, 150 mM imidazole, 0.1mM PMSF, 0.2 mM DTT, 25% glycerol.

Legal Information

PRECISIO is a registered trademark of Merck KGaA, Darmstadt, Germany

pictograms

GHS08,GHS07

signalword

Danger

hcodes

H315,H319,H360D

pcodes

P202 - P264 - P280 - P302 + P352 - P305 + P351 + P338 - P308 + P313

Hazard Classifications

Eye Irrit. 2 - Repr. 1B - Skin Irrit. 2

Storage Class

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

wgk

WGK 1

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Faceshields, Gloves, multi-purpose combination respirator cartridge (US)

Regulatory Information

新产品

This item has

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Therapeutic potential of inhibiting Bruton's tyrosine kinase, (BTK).

A O Vassilev et al.

Current pharmaceutical design, 10(15), 1757-1766 (2004-06-08)

BTK (Bruton's tyrosine kinase) is a member of the TEC family of tyrosine kinases that plays a central but diverse modulatory role in various cellular processes. The unique role of BTK in a multitude of signaling pathways, its function as

Binding of Bruton's tyrosine kinase to Fyn, Lyn, or Hck through a Src homology 3 domain-mediated interaction.

G Cheng et al.

Proceedings of the National Academy of Sciences of the United States of America, 91(17), 8152-8155 (1994-08-16)

Bruton's tyrosine kinase (Btk) is a recently described B-cell-specific tyrosine kinase. Mutations in this gene lead to human X chromosome-linked agammaglobulinemia and murine X-linked immunodeficiency. Although genetic evidence strongly suggests that Btk plays a crucial role in B-lymphocyte differentiation and

p65BTK is a novel potential actionable target in KRAS-mutated/EGFR-wild type lung adenocarcinoma.

Federica Giordano et al.

Journal of experimental & clinical cancer research : CR, 38(1), 260-260 (2019-06-16)

Lung cancer is still the main cause of cancer death worldwide despite the availability of targeted therapies and immune-checkpoint inhibitors combined with chemotherapy. Cancer cell heterogeneity and primary or acquired resistance mechanisms cause the elusive behaviour of this cancer and

Global Trade Item Number

SKU	GTIN
B4312-10UG	04061837749902
B4312-100UG	04061833252420

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service